Alpine Immune Sciences (ALPN)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	33.28 mm	33.28 mm	33.28 mm	33.28 mm	33.28 mm	33.28 mm
Cash burn (monthly)	3.64 mm	(no burn)	7.57 mm	3.90 mm	9.23 mm	6.71 mm
Cash used (since last report)	37.24 mm	n/a	77.51 mm	39.99 mm	94.56 mm	68.77 mm
Cash remaining	-3.96 mm	n/a	-44.22 mm	-6.70 mm	-61.28 mm	-35.49 mm
Runway (months of cash)	-1.1	n/a	-5.8	-1.7	-6.6	-5.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

ALPN institutional ownership history Ownership history

20.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	4	178	-97.8%
Opened positions	0	69	EXIT
Closed positions	174	22	+690.9%
Increased positions	0	59	EXIT
Reduced positions	1	38	-97.4%

13F shares	Current	Prev Q	Change
Total value	548.93 mm	2.04 tn	-100.0%
Total shares	13.82 mm	69.01 mm	-80.0%
Total puts	0.00	199.40 k	EXIT
Total calls	0.00	158.40 k	EXIT
Total put/call ratio	–	1.3	–

Largest owners	Shares	Value	Change
Decheng Capital China Life Sciences USD Fund III	6.58 mm	$309.64 mm	0.0%
Frazier Life Sciences VIII	3.20 mm	$207.03 mm	-0.0%
Alpine ImmunoSciences	2.68 mm	$32.27 mm	0.0%
Biotechnology Value Fund L P	1.35 mm	$0.00	0.0%

Largest transactions	Bought/sold	Change
Avoro Capital Advisors	-5.78 mm	EXIT
BLK BlackRock	-3.58 mm	EXIT
Frazier Life Sciences Management	-3.13 mm	EXIT
T. Rowe Price	-3.08 mm	EXIT
STT State Street	-2.85 mm	EXIT
Vanguard	-2.71 mm	EXIT
Cormorant Asset Management	-2.70 mm	EXIT
Orbimed Advisors	-2.68 mm	EXIT
Lynx1 Capital Management	-2.25 mm	EXIT
Paradigm Biocapital Advisors	-2.12 mm	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ALPN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 May 24	Remy Durand	Common Stock	Sale back to company	Dispose D	No	No	0	31,200	0.00	0
20 May 24	Remy Durand	Common Stock	Sale back to company	Dispose D	No	No	0	102,192	0.00	31,200
20 May 24	Remy Durand	Stock Option Common Stock	Sale back to company	Dispose D	No	No	18.33	78,000	1.43 mm	0
20 May 24	Remy Durand	Stock Option Common Stock	Sale back to company	Dispose D	No	No	7.55	109,000	822.95 k	0
20 May 24	Remy Durand	Stock Option Common Stock	Sale back to company	Dispose D	No	No	13.3	112,500	1.50 mm	0
20 May 24	Remy Durand	Stock Option Common Stock	Sale back to company	Dispose D	No	No	13.2	70,155	926.05 k	0
20 May 24	Remy Durand	Stock Option Common Stock	Sale back to company	Dispose D	No	No	3.23	26,922	86.96 k	0
20 May 24	Remy Durand	Stock Option Common Stock	Sale back to company	Dispose D	No	No	4.09	2,635	10.78 k	0
20 May 24	Ulrich Martin Fuhs	Common Stock	Sale back to company	Dispose D	No	No	0	7,300	0.00	0
20 May 24	Ulrich Martin Fuhs	Common Stock	Sale back to company	Dispose D	No	No	0	22,820	0.00	7,300

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

9 Jan 25

Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture